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Disulfide bonds are important structural motifs that play an essen-
tial role inmaintaining the conformational stability of many bioactive
peptides. Of particular importance are the conotoxins, which selec-
tively target awide rangeof ion channels that are implicated innumer-
ous disease states. Despite the enormous potential of conotoxins as
therapeutics, their multiple disulfide bond frameworks are inher-
ently unstable under reducing conditions. Reduction or scrambling
by thiol-containing molecules such as glutathione or serum albu-
min in intracellular or extracellular environments such as blood
plasma can decrease their effectiveness as drugs. To address this
issue, we describe a new class of selenoconotoxins where cysteine
residues are replaced by selenocysteine to form isosteric and non-
reducible diselenide bonds. Three isoforms of-conotoxin ImI were
synthesized by t-butoxycarbonyl chemistry with systematic replace-
mentofone([Sec2,8]ImIor [Sec3,12]ImI),orboth([Sec2,3,8,12]ImI)disul-
fide bonds with a diselenide bond. Each analogue demonstrated
remarkable stability toreductionorscramblingunderarangeofchem-
ical and biological reducing conditions. Three-dimensional structural
characterization by NMR and CD spectroscopy indicates conforma-
tional preferences that are very similar to those of native ImI, suggest-
ing fully isomorphic structures. Additionally, full bioactivity was
retained at the 7 nicotinic acetylcholine receptor, with each seleno-
analogueexhibitingadose-responsecurve thatoverlapswithwild-type
ImI, thus further supporting an isomorphic structure. These results
demonstrate that selenoconotoxins can be used as highly stable scaf-
folds for the design of new drugs.
A major goal in peptide-based drug design is to increase conforma-
tional stability to gain greater selectivity for a receptor target and
enhanced resistance to degradation by proteases. Traditionally, cycliza-
tion is employed as a means of restricting a peptide to the bioactive
conformation, which consequently increases receptor selectivity and
in vivo stability (1). Nature has successfully implemented this strategy
through disulfide bonds, which form single ormultiple intrachain cross-
links that impart considerable structural constraints and contribute to
stabilizing the bioactive conformation. Some biologically important
peptides containing disulfide bonds have also achieved drug status or
are currently in clinical trials (Table 1).
Whereas disulfide bonds impart conformational stability to peptides
and proteins, they are inherently unstable in reducing environments
and are susceptible to disulfide bond exchange reactions with biological
thiols such as glutathione (2). Glutathione primarily functions as an intra-
cellular redox buffer with the intracellular concentration of reduced gluta-
thione being in the millimolar range (2–5 mM) inside mammalian cells.
Surprisingly, glutathione also occurs in the reduced form in the micro-
molar range in blood plasma and may play a role in disulfide bond
deactivation through scrambling or trapping processes (3). Similarly,
redox-active enzymes, including thioredoxin and disulfide isomerase,
which control a variety of processes through thiol redox control, can
lead to reduction of disulfide bonds (4, 5). Scrambling of the disulfide
bond connectivity has been shown to induce structural changes that can
lead to reduced biological activity (6). From a drug design perspective,
this can result in reduced potency or potentially harmful side effects.
Selenocysteine (Sec)2 is a naturally occurring amino acid, which
forms an essential catalytic group in several redox enzymes (7). Its
unique redox properties make it a useful mechanistic probe for creating
artificial catalystswith novel hydrolytic and redox activities (8–10). Fur-
thermore, selenocysteine exhibits the propensity to oxidatively form a
diselenide bond analogous to the disulfide bond (11). Replacement of a
disulfide bond with a diselenide bond may be viewed as one of the most
highly conservative substitutions available. Early studies showed that
replacement of a single disulfide bond by the diseleno isostere in oxyto-
cin (12), somatostatin (13), and rat atrial natriuretic peptide (14) led to
analogues having biological activities similar to the native peptide. Fur-
ther, conformational studies by Moroder and co-workers (15) of a dis-
elenide bond analogue of endothelin-1 indicated that considerable
native secondary structure may be maintained. It would appear that the
use of selenocysteine substitution of disulfide bonds has significant
advantages over substitution with other chemical moieties, including
carba (16, 17), lactam (18), and thioether bridges (19), which can impart
structural distortions that may compromise bioactivity and selectivity.
Despite the similarities between cysteine and selenocysteine, their
chemical properties differ quite considerably. Reactions with selenocys-
teine occur much faster than cysteine at pH 5.0, suggesting that seleno-
cysteine can be selectively oxidized over cysteine at lower pH (20). The
redox potential relative to glutaredoxin for the diselenide bond (381
mV) is significantly lower than that of the disulfide bond (180 mV),
requiring stronger reducing conditions, such as a large excess of dithi-
othreitol or sodium borohydride, to induce its cleavage (21). Further-
more, the redox potential for a mixed sulfide/selenide bond is higher
than that of a diselenide bond (321mV), suggesting that its formation
is unfavorable. Therefore, we would anticipate that diselenide bonds,
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once formed, would eliminate the possibility of scrambling under bio-
logical reducing conditions.
Conotoxins are a class of disulfide-rich peptide neurotoxins isolated
from the venom of carnivorous marine snails. They target a wide range
of ion channels with a high degree of selectivity and potency and have
profound therapeutic potential, with at least one example recently
approved as a drug for the treatment of chronic pain and several others
currently undergoing clinical trials (see Table 1) (22). In the present
study, we have investigated the impact of substituting disulfide bonds
with diselenide bonds on the structure, activity, and conformational
stability of a model cysteine-rich peptide in relevant biological reducing
environments. Conotoxin ImI is a potent antagonist of the neuronal 7
nicotinic acetylcholine receptor (nAChR) (23), and its structure and
function are well characterized (24–26). It comprises 12 amino acid
residues with two internal disulfide bonds (Fig. 1) that are substantially
“buried” within the three-dimensional structure. In its native form,
disulfide bonds occur between residues 2 and 8 and residues 3 and 12;
however, the presence of two disulfide bonds gives rise to the possibility
of accessing two additional monomeric isomers, namely the 2–12 and
3–8 (ribbon) or 2–3 and 8–12 (beads) isomers through thiol-induced
scrambling. Here we describe (i) the development of a general chemical
procedure for the synthesis of selenocysteine- and diselenide-contain-
ing peptides that overcomes previous chemical limitations; (ii) the syn-
thesis of novel analogues of -conotoxin ImI, where one ([Sec2,8]ImI
and [Sec3,12]ImI) and both ([Sec2,3,8,12]ImI) disulfide bonds are system-
atically replaced with diselenide bonds; (iii) evaluation of the three-
dimensional structures of the above analogues; (iv) characterization of
their potency on rat 7 nAChRs expressed in Xenopus oocytes; and (v)
evaluation of their stability to reduction and scrambling in several bio-
logical environments. On the basis of the experimental data, we suggest
that this new class of bioactive peptides, the selenoconotoxins, has sig-
nificantly improved properties that enhance their potential for drug
development.
MATERIALS ANDMETHODS
Synthesis of Boc-Sec(MeBzl)-OH
DisodiumDiselenide (Na2Se2)—A 1M solution of Na2Se2 (50 ml) was
prepared according to the method of Klayman and Griffin (27) and was
immediately used for subsequent reactions.
L-Selenocystine was prepared as described previously by Chocat et al.
(28) from H--chloro-L-alanine and sodium diselenide (4.62 g, 70.2%).
1H NMR (300MHz, D2ODClDSS)  4.5 (m, 1H), 3.5 (m, 2H); 13C
NMR (75.4 MHz, D2O DCl DSS)  168.8, 51.6, 25.3.
Se-(4-methylbenzyl)-L-selenocysteine—Selenocystine (3.80 g, 9.3 mmol)
was suspended in 1 MNaOH (15ml). Themixture was cooled to 0 °C, and
sodiumborohydride (3.60g, 11.4mmol) inwater (15ml)wasadded in small
portions with stirring. After the vigorous reaction had subsided and the
mixture had become a colorless solution (30 min), the pH was carefully
adjusted to 7 using glacial acetic acid under a blanket of argon. -Bromo-
p-xylene (1.11g, 60mmol) in ethanol (15ml)was thenaddeddropwiseover
30 min, and the solution was stirred for a further 2 h at 0 °C under argon.
The mixture was then acidified to pH 2 with 6 M HCl, producing a white
precipitate, which was filtered, washed with diethyl ether (3 50 ml), and
dried under vacuum. Thewhite powder was dissolved in boiling water and
precipitated upon cooling to give H-Sec(MeBzl)-OH as a crystalline solid
(3.50 g, 61.1%). 1H NMR (300MHz, CD3ODDClDSS)  7.2 (d, 2H),
7.1 (d, 2H), 4.1 (q, 1H) 3.8, (s, 2H), 3.0 (m, 1H), 2.3 (s, 3H); 13C NMR (75.4
MHz, CD3OD DCl)  170.7, 138.0, 136.8, 130.3, 130.1, 53.9, 28.7, 23.2,
21.4.
N-tert-Butyloxycarbonyl-Se-(4-methylbenzyl)-L-selenocysteine—Se(4-
methylbenzyl)-L-selenocysteine (3.24 g, 10mmol) andK2CO3 (3.4 g, 0.15
mol) were dissolved in water (25ml) with gentle heating. Boc-dicarbon-
ate (2.30 g, 0.11 mol) in 1,4-dioxane (25 ml) was added, and the mixture
was stirred vigorously at room temperature for 1 h before water was
added (100 ml). The mixture was washed with diethyl ether (2  100
ml), and the aqueous layerwas acidified to pH4with solid citric acid and
extracted with ethyl acetate (3 100 ml). The combined extracts were
washed with 10% citric acid (3 100 ml), brine (100 ml) and then dried
over MgSO4 and filtered, and solvent was removed in vacuo to give
Boc-Sec(MeBzl)-OH as a white crystalline solid, which was recrystal-
lized from petroleum spirits/diethyl ether. (2.8 g, 75.3%) 1H NMR (300
MHz, CDCl3  tetramethylsilane)  7.14 (d, 2H), 7.02 (d, 2H), 5.29 (d,
2H), 3.79 (m, 2H), 2.87 (s, 2H), 2.32 (s, 3H), 1.45 (s, 9H); 13C NMR (75.4
MHz, CDCl3)  175.6, 155.4, 136.6, 135.4, 129.3, 128.8, 80.5, 53.3, 28.3,
27.8, 25.3, 21.1.
Peptide Synthesis
Assembly of WT ImI, [Sec2,8]ImI, [Sec3,12]ImI, and [Sec2,3,8,12]ImI
was performed manually using HBTU-mediated Boc in situ neutraliza-
tion solid phase peptide synthesis (SPPS) (29) on 4-methylbenzhy-
drylamine resin. Deformylation of tryptophan was carried out prior to
cleavage from the resin by treating with 20% ethanolamine, 10% H2O,
dimethylformamide. Cleavageswere performed by treating the peptide-
resin (300mg) with 10ml of HF/p-cresol/p-thiocresol (18:1:1, v/v/v) for
2 h at 0 °C. Following evaporation of the HF, in vacuo the crude
peptides were precipitated and washed with cold ethyl acetate
degassed with nitrogen (30 ml). The peptides were filtered under a
blanket of nitrogen and immediately oxidized by dissolving in 300 ml
FIGURE 1. -Selenoconotoxin analogues of ImI. Connectivity between cysteine/
selenocysteine residues is indicated.
TABLE 1
Representative peptide-based drugs that contain disulfide bonds
Name Status Disulfide bonds Mode of action Disease state
Somatostatin Approved 1 Inhibits hormone release Giantism and acromegaly
Oxytocin Approved 1 Oxytocin receptor agonist Uterotonic
Carperitidc Approved 1 Naturetic peptide receptor agonist Cardiovascular (heart failure)
Integrilin Approved 1 Platelet glycoprotein IIb/IIIa inhibitor Cardiovascular (antianginal)
Vasopressin Approved 1 Vasopressin receptor agonist Cardiovascular (antihypertensive)
Xen-2174 (-Ctx Mr1A) Phase II Clinical Trial 2 Noradrenaline transporter inhibitor Analgesic
ACV1 (-Ctx Vc1.1) Preclinical 2 nAChR antagonist Analgesic
Insulin Approved 3 Insulin receptor agonist Diabetes
Aprotinin Approved 3 Plasmin inhibitor Cardiovascular (antihemorrhagic)
Alfimcprasc Phase III Clinical Trial 3 Degrades fibrin Cardiovascular (thrombolytic)
Prialt (-Ctx MVIIA) Approved 3 Ca2 channel antagonist (N-type) Analgesic
AM-336 (-Ctx CVID) Phase II Clinical Trial 3 Ca2 channel antagonist (N-type) Analgesic
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of 0.1 M ammonium formate, 50% isopropyl alcohol (pH 4.2). For
[Sec2,8]ImI and [Sec3,12]ImI, the solution was adjusted to pH 8.2,
which allowed further oxidation to form the disulfide bond. Prior to
purification, the solution was acidified to pH 2 and analyzed by RP-
HPLC and electrospray ionization mass spectrometry to ensure com-
plete oxidation. The isopropyl alcohol was removed in vacuo, and the
peptide was isolated using preparative RP-HPLC. Yields from the pep-
tide-resin were as follows: 22% for [Sec2,8]ImI, 27% for [Sec3,12]ImI, 30%
for [Sec2,3,8,12]ImI.
Two-dimensional NMR Structural Studies
Samples used for 1H NMRmeasurements contained3 mM peptide
in 90% H2O, 10% D2O at pH 3.5. TOCSY and NOESY spectra were
acquired at 290 K using a Bruker 500- or 750-MHzNMR spectrometer.
NOESY spectra were acquired using 150-, 250-, and 300-ms mixing
times, and TOCSY spectra were acquired with an 80-ms mixing time.
1H chemical shifts were referenced to an internal sodium 2,2-dimethyl-
2-silapentane-5-sulfonate standard. Structures were calculated using
previously described or standardmethods (30). Briefly, initial structures
were calculated using DYANA (31), and these were refined using CNS
(32) to obtain an ensemble of 50 structures.
Electrophysiology Assay
RNA preparation, oocyte preparation, and expression of 7 nAChRs
inXenopus oocyteswere performed as described previously (33). Briefly,
plasmids with cDNA encoding the rat7 nAChR subunit were provided
by Dr. J. Patrick (Baylor College of Medicine, Houston, TX) and sub-
cloned into the oocyte expression vector pNKS2 (34). Oocytes were
injected with 50 nl of cRNA (50 ng/l) and then kept at 18 °C in ND96
buffer (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 5 mM
HEPES at pH 7.4) supplemented with 50mg/liter gentamycin and 5mM
pyruvic acid 2–8 days before recording.
Membrane currents were recorded from Xenopus oocytes using an
automated work station with eight channels in parallel, including drug
delivery and on-line analysis (OpusXpressTM 6000Awork station; Axon
Instruments, Union City, CA). Both the voltage-recording and current-
injecting electrodeswere pulled fromborosilicate glass (GC150TF;Har-
vard Apparatus Ltd., Edenbridge, UK) and filled with 3 M KCl with
resistances between 0.3 and 1.5 megaohms. All recordings were con-
ducted at room temperature (20–23 °C) using a bath solution of ND96
as described above. During recordings, the oocytes were perfused con-
tinuously at a rate of 1.5ml/min, with 200-s incubation times for the ImI
analogues. Acetylcholine was applied for 2 s at 4.8 ml/min, with 300-s
washout periods between applications. Cells were voltage-clamped at a
holding potential of100mV.Datawere sampled at 500Hz and filtered
at 200 Hz. Peak current amplitude was measured before and following
incubation of the ImI analogues.
Thiol Stability
Peptide samples (0.25 mM) were dissolved in a solution containing
either 0.25mM reduced glutathione, 12.3M reduced thioredoxin (Pro-
mega, Madison, WI) or 0.5 mM human serum albumin (Sigma) in 100
mM phosphate buffer plus 1 mM EDTA, pH 7.2 (300 l), and incubated
at 37 °C. Thioredoxin was reduced by treating the oxidized form with
0.9 eq of dithiothreitol for 15min immediately prior to use. Aliquots (30
l) were taken at various time intervals; quenched with extraction
buffer consisting of 50% aqueous acetonitrile, 100 mM NaCl, and 1%
trifluoroacetic acid (30 l); and analyzed by RP-HPLC. For conotoxin
ImI, the ratio of the nonnative isomer to the native isomer was deter-
mined by measuring the peak area.
Human Blood Plasma Stability
Whole human blood containing 1% EDTA was centrifuged at 14,000
rpm for 30 min. The supernatant was then transferred to an Eppendorf
tube and centrifuged for an additional 30 min at 14,000 rpm. Peptide
samples were dissolved in plasma (200 l) to an initial peptide concen-
tration of 0.25 mM. Aliquots (30 l) were removed at various time
intervals and quenched with extraction buffer (30 l). The aliquot was
then vortexed, dilutedwith additional water (60l), and chilled in an ice
bath for 5 min prior to centrifuging at 14,000 rpm for 15 min. The
supernatant was then analyzed by RP-HPLC.
RESULTS
General Strategy—The synthesis of selenocysteine-containing pep-
tides has been limited due to the considerable chemical difficulties expe-
rienced by several laboratories (35). Most of the chemistry developed to
date has employed the Fmoc-SPPS strategy and the Se-4-methoxyben-
zyl derivative. The (normal) use of auxiliary bases in the coupling and
deprotection steps is reported to induce -elimination and racemiza-
tion of the protected selenocysteine derivative (35). Despite the devel-
opment of optimized procedures that utilize minimal treatment with
piperidine for the stepwise removal of N-Fmoc protecting group (35),
these methods still lack general applicability. The N-Fmoc protecting
group can suffer from incomplete removal, thus reducing the quality
and yield of the final product, particularly in difficult peptide sequences
(36, 37). Moreover, it has been suggested that protected selenocysteine
derivatives can racemize, unless pentafluorophenyl esters are used in
subsequent chain elongation steps (35). The use of such derivatives is
also limited by their lack of commercial availability.
Recently, it has been suggested that Boc chemistry can overcome the
problems associated with the synthesis of selenocysteine-containing
peptides (38). In contrast to Fmoc chemistry, Boc-SPPS has the advan-
tage of clean and reliableN-Boc deprotection under acidic conditions,
thus ensuring high yields during chain assembly (39) and avoiding
excessive exposure to base, which compromises selenocysteine integrity
(35). Additionally, the use of Boc in situ neutralization coupling chem-
istry (29) would be expected to suppress racemization, since couplings
are performed at neutral pH, allowing the use of commonly available
protected amino acid derivatives. The S-4-methylbenzyl (S-MeBzl) pro-
tecting group is generally used in Boc-SPPS for the protection of cys-
teine (40). In early studies, Se-MeBzl was successfully employed by Soda
and co-workers (41) for protection of selenocysteine, although no fur-
ther examples of its use have been reported, and no experimental data
were reported for the synthesis of the selenocysteine derivative. In our
opinion, Boc-Sec-MeBzl-OH is the derivative of choice for Boc-SPPS,
since the protecting group is stable to the repetitive trifluoroacetic acid
treatments required for the stepwise removal of the N-Boc protecting
group, and its deprotection byHF acidolysis yields the free selenol func-
tionality under nonoxidizing conditions.
Boc-L-Sec(MeBzl)-OH was prepared in three steps from -chloro-L-
alanine as previously described (41) and fully characterized. Following
synthesis, the dipeptidewith L-leucinewas formed on resin, and analysis
of the cleaved product by RP-HPLC confirmed that no racemization
had occurred, as judged by the presence of a single peak. The propensity
for the Se-MeBzl protected derivative to undergo -elimination and
racemization under a variety of conditions was further investigated.
The dipeptide-resinwas subjected to a range of basic conditions, includ-
ing treatment with 20% ethanolamine, 10% H2O, 50% piperidine, 50%
DBU, 10% diisopropylethylamine, and 10% N-methylmorpholine in
dimethylformamide. The presence of -elimination and racemization
products was investigated by analytical RP-HPLC. Although no signifi-
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cant amount of racemization was detected under any of these condi-
tions,1% racemization was observed following a 24-h treatment with
50% DBU. No evidence of -elimination products was observed under
any of these conditions. The absence of problematic side reactions dem-
onstrates that the Se-MeBzl protecting group is highly suitable for use in
solid phase peptide synthesis.
Synthesis of -Selenoconotoxin Analogues—Solid phase assembly of
each peptide was performed using HBTU-mediated couplings with
Boc in situ neutralization chemistry on 4-methylbenzhydrylamine
cross-linked polystyrene resin (29). Deformylation of tryptophan
prior to HF cleavage was achieved using 20% ethanolamine, 10%H2O
in dimethylformamide. Acidolytic cleavage of the peptides was per-
formed using HF/p-cresol/p-thiocresol (90:5:5) for 2 h at 0 °C. Pre-
cipitation of the crude peptide with ethyl acetate afforded the
reduced peptide, which was shown to be free of -elimination and
racemization products.
FIGURE 2. Synthesis of-selenoconotoxin analogues. Top, crude analytical RP-HPLC following HF cleavage and oxidation. Themain peak (A) was isolated by preparative RP-HPLC
as shown in the center panel. The presence of a second earlier eluting peak (B) was found to have an identical mass corresponding to each -selenoconotoxin analogue. Bottom,
electrospray ionizationmass spectrometry ([Sec2,8]ImI found 1447.74 0.8 Da, calculated 1447.18 Da; [Sec3,12]ImI found 1447.74 0.8 Da calculated 1447.18; [Sec2,3,8,12]ImI found
1541.80 1.2 Da, calculated 1542.80 Da).
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Whereas the fully reduced peptides were successfully isolated follow-
ing cleavagewithHF, common laboratory handling and storage resulted
in oxidative degradation of the reduced material. In considering the
difficulties associated with long term storage, the reduced selenocys-
teine-containing peptides were immediately oxidized in aqueous buffer
followingHF cleavage (Fig. 2, top). Crude reduced peptidewas dissolved
in aqueous 0.1 M ammonium formate buffer at pH 4.2, containing 50%
isopropyl alcohol and oxidized in an open vessel. The oxidation progress
was efficientlymonitored by electrospray ionizationmass spectrometry,
where the loss of 2 atomicmass units in theMH/2 ion corresponds to
the formation of the diselenide bond (Fig. 2, bottom). Oxidation of
[Sec2,3,8,12]ImI proceeded rapidly to completion at pH 4.2, to yield one
major product. A second product with identical mass corresponding to
a second isomer of [Sec2,3,8,12]ImI was designated as the 1–4, 2–3 iso-
mer (ribbon), since its retention time was found to be similar to theWT
ImI ribbon isomer (Fig. 2, top). The formation of the strained 1–2, 3–4
(beads) is not observed in the oxidation ofWT ImI andwas not observed
in the oxidation of the selenoconotoxins.
At pH 4.2, the diselenide bond in [Sec2,8]ImI and [Sec3,12]ImI is selec-
tively formed over the disulfide bond, to give the partially oxidized peptide.
The solution was adjusted to pH 8.2 in situ, allowing formation of the
disulfide bond to give fully oxidized native [Sec2,8]ImI and [Sec3,12]ImI
almost exclusively.However, a small amountof a second isomer (1%)was
alsoattributed to theribbon isomerdue to its retention timenearly identical
to that of the WT ribbon isomer and mass identical to that of the native
selenoconotoxins. Similarly, the presence of the beads isomer was not
detected. The native isomer of each analoguewas isolated in high yield and
purity by preparative RP-HPLC (Fig. 2, center).
A comparison of RP-HPLC retention times showed that although
[Sec2,8]ImI co-eluted with WT ImI, [Sec3,12]ImI and [Sec2,3,8,12]ImI
demonstrated a slightly longer retention time. This is presumably a
result of the exposure of the relatively hydrophobic diselenide bond
between residues 3 and 12 to the hydrophobic stationary phase of the
RP-column.
Structural Studies—CD spectroscopy was used to confirm that suc-
cessful folding of the analogues was achieved. The CD spectra of each
analogue indicated a conserved overall fold, displaying characteristic
helical elements that indicate successful folding to achieve the correct
connectivity between respective cysteine and selenocysteine residues
(Fig. 3A).
1H NMR was used to determine the three-dimensional structures of
[Sec2,8]ImI and [Sec2,3,8,12]ImI for comparison withWT ImI. Each ana-
FIGURE 3. Structural studies of-selenoconotoxin ImI analogues. Circular dichroism spectra (A) and a comparison of the NH (B) and H (C) backbone chemical shifts are shown.
WT ImI shifts fromGehrmann et al. (24) were used. Secondary chemical shifts were calculated by subtracting random coil values (54) from the observed chemical shifts.F, WT ImI;E,
[Sec2,8]ImI; Œ, [Sec3,12]ImI; ‚, [Sec2,3,8,12]ImI. D, overlay of the backbones (N, C, and CO atoms) and of the disulfide and diselenide bonds of the 20 minimum energy conformers
representing the [Sec2,8]ImI and [Sec2,3,8,12]ImI NMR-derived structures. Disulfide bonds are shown in red, and diselenide bonds are shown in yellow. E, ribbon representations of
[Sec2,8]ImI and [Sec2,3,8,12]ImI. WT ImI is shown for comparison (25). F, overlays of the minimum energy structures of [Sec2,8]ImI and [Sec2,3,8,12]ImI with WT ImI (left and middle,
respectively) and overlay of [Sec2,8]ImI on [Sec2,3,8,12]ImI (right).
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logue gaveNMR spectra with goodNH chemical shift dispersion, indic-
ative of a well structured molecule. Resonances in spectra were identi-
fied by the sequence-specific assignment procedure (42), and similar
trends in secondary H chemical shifts indicated a conserved three-
dimensional structure of the analogues. A negative deviation from the
random coil backboneH shifts indicated a helical structure, consistent
with previously determined structures of WT ImI, thus providing fur-
ther confirmation that each analogue correctly folded to the native iso-
mer (Fig. 3, B and C).
NOE and dihedral restraints were used to generate three-dimen-
sional structures via simulated annealing calculations for [Sec2,8]ImI
and [Sec2,3,8,12]ImI. A total of 70NOE distance restraints (39 sequential,
11 medium, and 20 long range) excluding intraresidue restraints and
seven dihedral angle restraints were used for [Sec2,8]ImI, and 68 NOE
distance restraints (36 sequential, 11 medium, and 21 long range) and
six dihedral angle restraints were used for [Sec2,3,8,12]ImI. A family of 50
structures was generated with no NOE violations of 0.2 Å and no
dihedral violations of 2°. The 20 lowest energy structures were
selected for the final ensemble, with mean backbone root mean square
deviation values of 0.50  0.2 Å for [Sec2,8]ImI and 0.44  0.18 Å for
[Sec2,3,8,12]ImI (Fig. 3D). The minimum energy structures were super-
imposed with the structure of WT ImI, demonstrating that conforma-
tional preferences for the diselenide-containing analogues are very sim-
ilar to that ofWT ImI (Fig. 3E). The structures show that the diselenide
bond between residues 2 and 8 is buried within the core, but the bond
between residues 3 and 12 is more exposed, thus rationalizing the
observed difference in RP-HPLC retention time.
Electrophysiology—The biological activity of each analogue com-
pared with WT ImI was examined in an electrophysiology assay by
measuring the inhibition of each analogue at the rat 7 nAChR exp-
ressed inXenopus oocytes. Membrane currents were activated with 200
M acetylcholine, amaximally effective concentration (Fig. 4A). A com-
parison of concentration-response relationship curves for each ana-
logue further demonstrated a negligible difference in activity compared
with WT ImI at the 7 nAChR (Fig. 4B). Calculation of the IC50 values
and Hill coefficients using the empirical Hill equation showed that bio-
activity is conserved for each of the analogues within the limits of error
(Table 2). The retention of bioactivity in all three diselenide-ImI ana-
logues further supports structures isomorphic to WT ImI.
Stability Studies—Blood plasma stability was used to assess the sta-
bility of the analogues in vivo. Reducing thiols are well known to be
present in human blood plasma with their concentrations ranging from
low to mediummicromolar levels (43), which can potentially reduce or
scramble the disulfide bond framework of disulfide-rich peptides (Fig.
5A) (44). Incubation of 0.25 mM WT ImI in human blood plasma
showed that the low levels of thiols present are indeed sufficient to
rearrange the disulfide framework, as characterized by the presence of
an earlier eluting peak over time that was identified as the ribbon isomer
(Fig. 5B). The ratio of the peak areas can be represented as percentage
scrambling, where a 1:1 ratio of ribbon to native isomer represents 100%
scrambling (Fig. 5C). The presence of an additional peak on RP-HPLC,
corresponding to the ribbon isomer was not observed for each of the
-selenoconotoxins, upon incubation in blood plasma. Since the ribbon
isomer of each -selenoconotoxin analogue is well resolved by RP-HPLC,
this suggests total stability to scramblingor reduction for these analogues in
blood plasma.
To examine the extent by which external thiols influence the scram-
bling of theWT ImI disulfide framework, a 0.25mM solution ofWT ImI
was treated with 1 eq of glutathione. Under these conditions, it was
shown that complete scrambling of the disulfide bond framework
occurs rapidly for WT ImI (approximately 6 h) (Fig. 5D). Importantly,
no evidence of scrambling or reduction was detected for any of the
diselenide analogues.
Albumin constitutes the most significant blood plasma protein,
occurring at a concentration of 0.6 mM (45). Approximately 70% of
albumin is present as mercaptalbumin, which consists of 17 disulfide
bonds and one free and highly reactive cysteine residue, Cys34 (45). It is
known that Cys34 can interact with other disulfide-containing com-
pounds, notably cystine or oxidized glutathione, through an intramo-
lecular disulfide exchange reaction at alkaline pH (46). Preliminary
experiments inour laboratoryhave indicated thatmercaptalbumin induces
significant disulfide bond scrambling in disulfide-containing peptides. The
drug candidates carperitide (human atrial natriuretic peptide) and
AM-336 (-conotoxinCVID) (SeeTable 1)were incubatedwith 0.6mM
FIGURE 4.Effect of-selenoconotoxin ImI analogues on rat7 nAChRs expressed in
Xenopus oocytes. A, superimposed traces of acetylcholine-evoked currents in the
absence (control, recovery) andpresence of 100 nM ImI and ImI analogues. Oocyteswere
voltage-clamped at 100 mV, and membrane currents were evoked with 200 M ace-
tylcholine.B, concentration-response curvesobtainedwith200mMacetylcholine follow-
ing200-s incubationofWT ImI (F), [Sec2,8]ImI (E), [Sec3,12]ImI (Œ), and [Sec2,3,8,12]ImI (‚).
Data represent the mean S.E. (n 8–12).
TABLE 2
Inhibition of acetylcholine-evoked currents by diselenide-containing
ImI analogues at rat 7 nAChRs expressed in Xenopus oocytes
Analogue IC50 H n
nM
WT ImI 69.3 15.5 0.8 0.2 10
[Sec2,8]ImI 49.5 16.2 0.7 0.2 9
[Sec3,12]ImI 50.3 8.4 0.7 0.1 12
[Sec2,3,8,12]ImI 49.7 6.0 0.8 0.1 8
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human mercaptalbumin to determine the effect on their disulfide bond
frameworks. In those experiments, several disulfide bond isomers were
present in the AM-336 reaction mixture, and a time-dependent
decrease (trapping) was observed for human atrial natriuretic peptide
(data not shown). Similarly, WT ImI was shown to undergo disulfide
scrambling. By contrast, none of the selenocysteine-containingmutants
showed any evidence of scrambling under identical conditions (Fig. 5E).
Thioredoxin is a redox-active enzyme that is secreted by cells and is
important in a variety of biological processes, including DNA replica-
tion and redox control (47). This redox enzyme contains two cysteine
residues in its active site. In its reduced form, thioredoxin is a powerful
protein disulfide reductase and therefore was used in these stability
studies. The selenocysteine-containing -conotoxin ImI analogues and
WT ImI were treated with thioredoxin at a concentration of 12.3 M. It
was shown that whereas scrambling is induced in the two disulfide
bond-containing WT ImI (Fig. 5F) none of the diselenide analogues
showed any evidence of reduction or scrambling.
DISCUSSION
Although we are witnessing the increased use of cystine-stabilized
bioactive peptides as therapeutic candidates, the susceptibility of those
candidates to reduction in vivo has, until now, failed to be addressed.
This study describes the synthesis and application of a new class of
bioactive peptides, the -selenoconotoxins, with properties suitable for
their use as peptide drugs.
The synthesis of diselenide-containing -conotoxin ImI analogues
was undertaken by highly optimized Boc chemistry, where introduction
of the selenocysteine residues was achieved using activated Boc-L-Sec-
(MeBzl)-OH. The products obtained using these methods were free of
racemic and -elimination side products that have plagued researchers
employing Fmoc chemical strategies. These procedures may also be
extended to other classes of selenocysteine-containing peptides, includ-
ing use in the synthesis of larger selenoproteins through selenocysteine-
mediated native chemical ligation and expressed protein ligation (20, 48,
49). A major advantage of our synthetic procedure is that formation of
the diselenide bonds is readily achieved bymild aerobic oxidation of the
reduced selenocysteine-containing peptide following cleavage with HF.
This is in contrast to previous methods that utilize oxidative deprotec-
tion of the Se-methoxybenzyl protected selenocysteine using iodine or
dimethyl sulfoxide, increasing the risk of potential side reactions that
are known to occur in sensitive side chains, such as Trp, His, Met, and
Tyr (50, 51).
Conformational studiesbyCDandNMRspectroscopy indicate that cor-
rect cross-linking was achieved for [Sec2,8]ImI and [Sec3,12]ImI. This was
anticipated given that correct pairing was driven by the differences
in redox potential between cysteine and selenocysteine and that the
formation of a mixed sulfide/selenide bond is generally unfavored.
Moreover, the correct pairing of selenocysteine residues in the two dis-
elenocysteine bond-containing [Sec2,3,8,12]ImI was achieved as the
major product without the use of regioselective pairing of selenocys-
teine residues (24). This suggests that formation of the diselenide bonds
is a cooperative process with the correct fold driven by similar factors
that influence the cysteine-rich homolog. Three-dimensional structure
calculations of the diselenide-containing -conotoxin ImI analogues
indicate structures isomorphic with WT ImI. Structural integrity was
further supported by electrophysiology assays at the rat 7 nAChR, in
which each of the diselenide-containing analogues exhibited similar
activity to WT ImI. Furthermore, complete replacement of the disul-
fide-bonding framework with diselenide bonds yielded a fully isomor-
phicmolecule. The results show that the use of selenocysteine is a highly
conservative substitution relative to other modifications, and, in buried
cysteine-rich frameworks such as the -conotoxins, selenocystine can
be accommodated even given the marginally longer carbon-selenium
(1.80 Å) and selenium-selenium (2.02 Å) bond lengths.3
Through a careful examination of the stability of the wild type and dis-
elenide-containing -conotoxin ImI isoforms in human blood plasma, we
observedsignificant scrambling inWTImI,witha1:1 ratioofnative/ribbon
3 Estimated by measurement of various diselenide-containing organic compounds
deposited in the Cambridge crystallographic data base (53).
FIGURE 5. Stability studies of-selenoconotoxin ImI analogues. A, proposedmechanism for scrambling of WT ImI to the ribbon isomer by external thiols. B, RP-HPLC analysis of
scrambling of 0.25 mM WT ImI in human blood plasma (containing 1% ETDA) over time. Shown is the disulfide framework stability of 0.25 mM ImI analogue in human blood plasma
(C); 0.25 mM glutathione (D); 0.6 mM human serum albumin (E), and 12.3 mM thioredoxin (F), 50 mM phosphate buffer plus 1 mM EDTA, pH 7.2, incubated at 37 °C. F, WT ImI;  ,
[Sec2,8]ImI;, [Sec3,12]ImI;ƒ, [Sec2,3,8,12]ImI. Analytical RP-HPLC peak areas of ribbon and native isomers weremeasured, and percentage scramblingwas calculated by determining
the ratio of the peak area of the ribbon isomer to the native isomer.
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isomer occurring within 24 h. Importantly, under identical conditions,
each of the diselenide analogues maintained complete structural integ-
rity with no evidence of scrambling occurring.Whereas we anticipated
that [Sec2,3,8,12]ImI would demonstrate complete stability in the
presence of reducing thiols, the substitution of just one disulfide
bond was found to be sufficient to achieve complete structural integ-
rity. Thus, [Sec2,8]ImI and [Sec3,12]ImI exhibited complete resistance
to reducing thiols, with no evidence of scrambling present. This can
be attributed to the difference in redox potential between cysteine and
selenocysteine, which disallows the formation of mismatched isomers
(52).
In summary, we anticipate that the isomorphic nature and high oxi-
dation potential of diselenide bondsmay find increasing use for probing
disulfide bonds in proteins and peptides. Furthermore, the superior
stability in human blood plasma exhibited by diselenide-containing iso-
forms of conotoxin ImI demonstrates their utility in designing stable
scaffolds for peptide-based drugs. Importantly, it appears that diseleno-
cysteine isoforms can be accommodated within cysteine-rich environ-
ments where significant burying of the cystine core has occurred.
REFERENCES
1. Kessler, H. (1982) Angew. Chem. Int. Ed. 21, 512–523
2. Rabenstein, D. L., and Weaver, K. H. (1996) J. Org. Chem. 61, 7391–7397
3. Meister, A., and Anderson, M. E. (1983) Annu. Rev. Biochem. 52, 711–716
4. Holmgren, A., and Bjornstedt, M. (1995)Methods Enzymol. 252, 199–208
5. Matthias, L. J., Yam, P. T. W., Jiang, X.-M., Vandegraaff, N., Li, P., Poumbourios, P.,
Donoghue, N., and Hogg, P. J. (2002) Nat. Immunol. 3, 727–732
6. Gehrmann, J., Alewood, P. F., and Craik, D. J. (1998) J. Mol. Biol. 278, 401–415
7. Stadtman, T. C. (2002) Annu. Rev. Biochem. 71, 1–16
8. House, K. L., Dunlap, R. B., Odom, J. D.,Wu, Z.-P., andHilvert, D. (1992) J. Am. Chem.
Soc. 114, 8573–8579
9. Gorlatov, S. N., and Stadtman, T. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95,
8520–8525
10. Lee, S.-R., Bar-Noy, S., Kwon, J., Levine, R. L., Stadtman, T. C., and Rhee, S. G. (2000)
Proc. Natl. Acad. Sci. U. S. A. 97, 2521–2526
11. Mu¨ller, S., Senn, H., Gsell, B., Vetter, W., Baron, C., and Bo¨ck, A. (1994) Biochemistry
33, 3404–3412
12. Walter, R., and du Vigneaud, V. (1965) J. Am. Chem. Soc. 87, 4192–4193
13. Hartrodt, B., Neubert, K., Bierwolf, B., Blech, W., and Jakubke, H. D. (1980) Tetrahe-
dron Lett. 21, 2393–2396
14. Koide, T., Itoh, H., Otaka, A., Furuya, M., Kitajima, Y., and Fujii, N. (1993) Chem.
Pharm. Bull. 41, 1596–1600
15. Pegoraro, S., Fiori, S., Rudolph-Bo¨hner, S.,Watanabe, T. X., andMoroder, L. (1998) J.
Mol. Biol. 284, 779–792
16. Nutt, R. F., Veber, D. F., and Saperstein, R. (1980) J. Am. Chem. Soc. 102, 6539–6545
17. Stymiest, J. L., Mitchell, B. F., Wong, S., and Verderas, J. C. (2003)Org. Lett. 5, 47–49
18. Hargittai, B., Sole´, N. A., Groebe, D. R., Abramson, S. N., and Barany, G. (2000) J.Med.
Chem. 43, 4787–4792
19. Bondebjerg, J., Grunnet, M., Jespersen, T., and Meldal, M. (2003) Chembiochem 4,
186–194
20. Hondal, R. J., Nilsson, B. L., andRaines, R. T. (2001) J. Am.Chem. Soc. 123, 5140–5141
21. Besse, D., Siedler, F., Dierks, T., Kessler, H., andMoroder, L. (1997)Angew. Chem. Int.
Ed. 36, 883–885
22. Armishaw, C. J., and Alewood, P. F. (2005) Curr. Protein Pept. Sci. 6, 221–240
23. McIntosh, J. M., Yoshikami, D., Mahe, E., Nielsen, D. B., Rivier, J. E., Gray, W. R., and
Olivera, B. M. (1994) J. Biol. Chem. 269, 16733–16739
24. Gehrmann, J., Daly, N. L., Alewood, P. F., and Craik, D. J. (1999) J. Med. Chem. 42,
2364–2372
25. Rogers, J. P., Luginbuhl, P., Shen, G. S., McCabe, R. T., Stevens, R. C., and Wemmer,
D. E. (1999) Biochemistry 38, 3874–3882
26. Maslannikov, I. V., Shenkarev, Z. O., Zhmak, M. N., Ivanov, V. T., Methfessel, C.,
Tsetlin, V. I., and Arseniev, A. S. (1999) FEBS Lett. 444, 275–280
27. Klayman, D. L., and Griffin, T. S. (1973) J. Am. Chem. Soc. 95, 197–199
28. Chocat, P., Esaki, N., Tanaka, H., and Soda, K. (1985) Anal. Biochem. 148, 485–489
29. Schno¨lzer, M., Alewood, P., Jones, A., Alewood, D., and Kent, S. B. H. (1992) Int. J.
Protein Pept. Res. 40, 180–193
30. Rosengren, K. J., Daly, N. L., Plan, M. R., Waine, C., and Craik, D. J. (2003) J. Biol.
Chem. 278, 8606–8616
31. Gu¨ntert, P., Mumenthaler, C., and Wu¨thrich, K. (1997) J. Mol. Biol. 273, 283–298
32. Bru¨nger, A. T., Adams, P. D., Clore, G.M., DeLano,W. L., Gros, P., Grosse-Kunstleve,
R. W., Jiang, J. S., Kuszewski, J., Nilges, M. J., Pannu, N. S., Read, R. J., Rice, L. M.,
Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sec. D 54, 905–921
33. Hogg, R. C., Hopping, G., Alewood, P. F., Adams, D. J., and Bertrand, D. (2003) J. Biol.
Chem. 278, 26908–26914
34. Gloor, S., Pongs, O., and Schmalzing, G. A. (1995) Gene (Amst.) 160, 213–217
35. Besse, D., and Moroder, L. (1997) J. Pept. Chem. 3, 442–453
36. Dryland, A., and Sheppard, R. C. (1986) J. Chem. Soc. Perkin Trans. 1, 125–137
37. Larsen, B. D., and Holm, A. (1994) Int. J. Protein Pept. Res. 43, 1–9
38. Moroder, L., Musiol, H.-J., Go¨tz, M., and Renner, C. (2005) Biopolymers 80, 85–97
39. Kent, S. B. H. (1988) Annu. Rev. Biochem. 57, 957–989
40. Live, D. H., Agosta, W. C., and Cowburn, D. (1977) J. Org. Chem. 42, 3556–3561
41. Oikawa, T., Esaki, N., Tanaka,H., and Soda, K. (1991)Proc. Natl. Acad. Sci. U. S. A. 88,
3057–3059
42. Wu¨thrich, K. (1986) NMR of Proteins and Nucleic Acids, pp. 130–161, JohnWiley &
Sons, Inc., New York
43. Dro¨ge, W. (2002) Exp. Gerontol. 37, 1331–1343
44. Singh, R. R., and Chang, J.-Y. (2003) Biochim. Biophys. Acta 1651, 85–92
45. Quinlan, G. J., Martin, G. S., and Evans, T. W. (2005) Hepatology 41, 1211–1219
46. Lipinski, B., and Egyud, L. G. (1992) Bioorg. Med. Chem. Lett. 2, 919–924
47. Holmgren, A. (1989) J. Biol. Chem. 264, 13963–13966
48. Quaderer, R., Sewing, A., and Hilvert, D. (2001) Helv. Chim. Acta 84, 1197–1206
49. Gieselman, M. D., Xie, L., and van der Donk, W. A. (2001) Org. Lett. 3, 1331–1334
50. Sieber, P., Kamber, B., Riniker, B., and Rittel, W. (1980) Helv. Chim. Acta 63,
2358–2362
51. Otaka, A., Koide, T., Shide, A., and Fujji, N. (1991) Tetrahedron Lett. 32, 1223–1226
52. Pegoraro, S., Fiori, S., Cramer, J., Rudolph-Bohner, S., andMoroder, L. (1999) Protein
Sci. 8, 1605–1613
53. Allen, F. H. (2002) Acta Crystallogr. Sect. B 58, 380–388
54. Wishart, D. S., Bigam, C. G., Holm, A., Hodges, R. S., and Sykes, B. D. (1995) J. Biomol.
NMR 5, 67–81
Improving the Biological Stability of Conotoxins
MAY 19, 2006•VOLUME 281•NUMBER 20 JOURNAL OF BIOLOGICAL CHEMISTRY 14143
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Craik and Paul F. Alewood
Christopher J. Armishaw, Norelle L. Daly, Simon T. Nevin, David J. Adams, David J.
Antagonists
 Neuronal Nicotinic Receptor7α-Selenoconotoxins, a New Class of Potent α
doi: 10.1074/jbc.M512419200 originally published online February 24, 2006
2006, 281:14136-14143.J. Biol. Chem. 
  
 10.1074/jbc.M512419200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/281/20/14136.full.html#ref-list-1
This article cites 53 references, 7 of which can be accessed free at
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
